



Eli Lilly and Co / LLY

Equity | Generated Sep 23, 2026 11:31 PM EDT

Current price	Daily move	Bid / Ask	Previous close
\$1,152.12	-18.02 -1.54%	\$1,150.50/\$1,154.88	\$1,170.14

Market	NYSE
Industry	Pharmaceuticals
Market data as of	Sep 23, 2026 11:31 PM EDT

JW Intelligence Report

Complete | 3 of 3 sections | Sep 23, 2026 6:50 PM EDT

JW Rank	Rank label	Confidence	IV percentile
59.8 / 100	Balanced	high	15 / 100
Model reference	Upside scenario	Risk reference	Wheel strategy fit
\$1,145.00	\$1,205.00	\$1,118.00	57 / 100

Options stance	neutral
Tail-risk safety	32 / 100
JW Rank data coverage / as of	100.0% Sep 23, 2026 6:50 PM EDT

Key insight

LLY Option Market Implies Balanced Outlook with Near-Term Volatility

Market read

The LLY option market currently reflects a neutral outlook, with implied volatility suggesting balanced potential for both upside and downside movement. While the stock price has declined recently, technical indicators are mixed, and there's no clear consensus on the direction of future price action. The term structure is in backwardation, indicating that near-term options are more expensive than longer-dated options.

Strategy context

LLY's recent price decline and upcoming earnings report could create volatility opportunities for option traders. However, the balanced skew and mixed technical signals suggest caution.



JW AI conclusions

Short- and medium-term model interpretation

AI context bias

Bearish

AI analysis updated

Sep 23, 2026 2:10 PM EDT

Short-term scenario

Cautious 1-3 week tactical long only on weakness into the 1135-1150 support area, targeting a bounce toward resistance rather than a breakout chase. Stand aside if price loses the 1130-1140 cluster on a closing basis. Not investment advice. Uncertainty is high: EASD headlines, sector flows, and ordinary ~\$30 ATR noise can stop out the trade or invalidate the bounce before any target is reached.

Three-month outlook

Moderately constructive with wide uncertainty, not a forecast. Base case into late December is a grind toward roughly 1200-1280 if Foundayo adoption, Medicare volume, and the early-November Q3 report support the \$85-87B revenue guide. A move to consensus 12-month targets (about 1325-1400) is unlikely to be fully realized in three months and needs clean data plus no pricing or competitive shock. Bear case is a de-rating toward about 1050-1120 if Novo competition, policy/pricing, or a guidance miss compresses the ~39x trailing multiple while price is already under the 50-day average. The Houston plant supports the multi-year supply story but does not add 2026 capacity. Retatrutide registration is still framed as a 2027 event. Any path is probabilistic.

Market sentiment

Recent X tone is thin and mixed-to-cautiously constructive, not a strong bullish or bearish consensus. One post listed a buy zone of 1120-1170. Others pointed to remaining GLP-1 runway versus Novo and relayed analyst actions including Guggenheim Buy with PT raised to 1284 and TD Cowen Buy with PT 1250. Same-day engagement was very low. Older valuation-skeptic posts exist but are not the current tape. Uncertainty: X is a noisy, non-representative sample of holders.

Supporting evidence

The 25-delta skew is balanced, suggesting neutral directional bias. | Implied volatility is elevated at 30.28%, reflecting potential for increased price swings in the coming weeks. | Technical indicators are mixed, with some showing signs of weakness while others suggest a potential bounce. | The term structure is in backwardation, indicating that near-term options are more expensive than longer-dated options.


Risk watch

Earnings risk: The next earnings report on October 29th could significantly impact LLY's stock price.



Enhanced price structure

45 trading days with volume, model levels and current technical reference bands




45 complete trading-session observations



JW Rank factors

Score, source coverage and interpretation for each decision factor



Decision summary

Primary model reads before the detailed indicator appendix

Momentum

bullish_recovery

Institutional flow

Below MVWAP

Structure

Above 200D trend

Volatility

medium



Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	BULLISH RECOVERY neutral MACD accelerating
Trend signal	BULLISH RECOVERY
RSI signal	neutral
RSI (7 / 14 / 21)	48.06 / 46.64 / 47.77
RSI velocity	-0.20
MACD line / signal / histogram	-8.39 / - / -11.46
MACD acceleration	1.77
Stochastic K / D	64.97 / 62.95

Institutional footprints

Volume-weighted cost, price location and flow

Current read	Below institutional MVWAP Distribution bias
Institutional flow	-4.49
20-day MVWAP	\$1,156.48
Price vs 20-day MVWAP	-0.38%
Daily reference VWAP	\$1,161.95
Price vs daily reference	-0.85%
Volume	968.89K

Structural context

Long-term trend and volatility boundaries

Current read	Above 200-day trend Negative macro velocity
Macro velocity	-4.17
20-day / 200-day SMA	\$1,150.82 / \$1,068.31
Bollinger range	\$1,110.98 - \$1,190.65
Bollinger position	0.502



Options and volatility intelligence


Structure, premium conditions and principal risks

IV rank	IV percentile	VVIX	SKEW
15 / 100	10 / 100	88.11	142.19

Market regime	DANGER ZONE
Tail-risk regime	NORMAL TAIL RISK
Term structure	backwardation
Term slope	-4.34 pts
Skew read	balanced
Liquidity / quote coverage	100.0%
Options Snapshot IV sources	ATM: option chain Rank/percentile: fundamentals
Options Snapshot IV observed at	Sep 23, 2026 2:54 PM EDT
Options data quality	Coverage 88.9%

Option term structure

ATM implied-volatility curve by days to expiration




EXPIRATION	DTE	ATM IV	STATE
2026-09-25	2	35.7%	-
2026-10-02	9	30.8%	-
2026-10-09	16	31.3%	-



Reference spread payoff

Illustrative expiry profit/loss per one-lot structure, including quoted net credit



Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	2026-10-29
Earnings IV-crush risk	NOT MEASURED
VIX	15.09
VVIX	88.11
SKEW index	142.19
Observation confidence	high
Option quote quality	reliable
Contracts observed	134



Event and tail-risk context (continued)

Known event windows and broad volatility conditions

FIELD	VALUE
Contracts with quotes	134

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

The LLY option market currently reflects a neutral outlook, with implied volatility suggesting balanced potential for both upside and downside movement. While the stock price has declined recently, technical indicators are mixed, and there's no clear consensus on the direction of future price action. The term structure is in backwardation, indicating that near-term options are more expensive than longer-dated options.

Options context

LLY Option Market Implies Balanced Outlook with Near-Term Volatility

Wheel context

LLY's recent price decline and upcoming earnings report could create volatility opportunities for option traders. However, the balanced skew and mixed technical signals suggest caution.

Observed evidence

The 25-delta skew is balanced, suggesting neutral directional bias. | Implied volatility is elevated at 30.28%, reflecting potential for increased price swings in the coming weeks. | Technical indicators are mixed, with some showing signs of weakness while others suggest a potential bounce. | The term structure is in backwardation, indicating that near-term options are more expensive than longer-dated options.

Principal risks to monitor

Earnings risk: The next earnings report on October 29th could significantly impact LLY's stock price.



Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization	P/E (TTM)
\$1.10T	40.21
ROE	Revenue growth
92.6%	31.7%
EPS growth	Operating margin
49.3%	42.2%
Net profit margin	Gross margin
33.5%	-
Free cash flow CAGR	Debt / equity
5.9%	1.60
Dividend yield	Beta
0.8%	0.43
52-week range	
\$712.05 - \$1,292.65	

Company or fund profile

Issuer identity and classification

Name	Market
Eli Lilly and Co	NYSE
Industry	Country
Pharmaceuticals	US
Currency	IPO date
USD	1970-07-09
Shares outstanding	52-week return
941.74M	54.9%
Book value per share	Revenue per share
\$35.98	\$89.14
Website	lilly.com



Latest strategy observation

Most recent shared general market signal available when this report was generated

LLY Covered Call signal	Sep 23, 2026 10:56 AM EDT
Covered Call 2026-10-02	
At signal \$1,162.23 Current \$1,152.12	
SHORT Option \$1,160.00 B \$23.70 / A \$27.45	
High turnover CR \$25.58	



Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	\$31.67
ATR as % of price	2.8%
Volatility environment	medium
Current IV	30.8%
IV rank	17 / 100
IV percentile	15 / 100
Technical Snapshot IV source	Private fundamentals snapshot
Technical Snapshot IV observed at	Sep 23, 2026 7:31 PM EDT

Technical health and risk radar

Derived indicator health and event context

Overall health	82 / 100
Trend health	78 / 100
Momentum health	85 / 100
Volatility health	69 / 100
Structure health	100 / 100
Earnings risk / date	low 2026-10-29
Macro risk	unknown
Volatility risk	medium
Structure risk	low

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	\$1,150.82 / \$1,176.62 / \$1,068.31
EMA (9 / 21)	\$1,152.49 / \$1,158.53
Bollinger upper / middle / lower	\$1,190.65 / \$1,150.82 / \$1,110.98



Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
Bollinger %B	0.502
True high / low	\$1,188.88 / \$1,145.98
5-day true high / low	\$1,188.88 / \$1,134.41

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	-4.166	-
SMA50	-0.247	-
MVWAP20	-4.495	-
MACD	1.771	-
RSI	-0.201	-
Volume	-83346.000	-
ATR	0.723	-
T1	-	-8.87 / 1161.21 / 1180.53 / 1139.26
T2	-	-11.30 / 1164.34 / 1170.90 / 1134.41
T3	-	-13.70 / 1169.97 / 1157.60 / 1140.27



Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	\$1,153.59
Options Snapshot IV sources	ATM: option chain Rank/percentile: fundamentals
Options Snapshot IV observed at	Sep 23, 2026 2:54 PM EDT
Options data coverage	88.9%
SKEW regime	HIGH TAIL RISK SKEW
VVIX regime	VVIX FALLING
Front expiration / DTE	2026-09-25 2 DTE
Front at-the-money IV	35.7%
25-delta skew	1.31
Put / Call 25-delta	\$1,132.50 Delta -0.245 / \$1,175.00 Delta 0.246
Median option bid/ask spread	18.4%
Bid/ask spread	-
Contracts observed / quoted	134 / 134

Price context

Last Price: 1,153.59 | Bid: 1,153.30 | Ask: 1,153.97 | Previous Close: 1,170.14 | Change: -16.55 |
Daily change: -1.41% | Update Time: 2026-09-23T14:54:48.235074-04:00 | Latest History Date: 2026-09-23
| Latest History Price: 1,153.59

Historical context

Trading-day sample: 60 sessions | First Date: 2026-06-30 | Latest Date: 2026-09-23 | Latest Price:
1,153.59 | Max Drawdown 60d Percent: -12.86%

Fundamental context

Current Iv Percent: 30.28% | Iv Rank: 14.63 | Iv Percentile: 10.36 | Next Earnings Date: 2026-10-29 |
Ex Dividend Date: 2026-08-13



Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Generated Sep 23, 2026 11:31 PM EDT. Jason Wheel Terms of Use and Privacy Policy apply. Copyright Jason Wheel Research LLC. All rights reserved.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	jasonwheel.com
Terms of Use	jasonwheel.com / Terms
Privacy Policy	jasonwheel.com / Privacy
Options Disclosure Document	theocc.com / Options Disclosure Document